The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Aileron Therapeutics; Merck Sharp & Dohme (I)
Stock and Other Ownership Interests - Aileron Therapeutics; Merck Sharp & Dohme (I)
Patents, Royalties, Other Intellectual Property - Aileron Therapeutics (Inst); Merck Sharp & Dohme (I)
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Mansoor N. Saleh
Honoraria - Genentech
Speakers' Bureau - Gilead Sciences; Novartis
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Sanjay Goel
Honoraria - Bayer; Genentech/Roche
Research Funding - Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Tesaro; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Pfizer; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Ki Y Chung
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
 
Robert Martin Conry
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Judy Sing-Zan Wang
No Relationships to Disclose
 
Ulrich Steidl
Consulting or Advisory Role - Aileron Therapeutics; Bayer; Celgene; GlaxoSmithKline; Novartis
Research Funding - Aileron Therapeutics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmacyclics (Inst)
 
Loren D. Walensky
Stock and Other Ownership Interests - Aileron Therapeutics
Consulting or Advisory Role - Aileron Therapeutics
Patents, Royalties, Other Intellectual Property - Dana Farber Cancer Hospital
 
Vincent Guerlavais
No Relationships to Disclose
 
Marie Payton
Employment - Aileron Therapeutics; Verastem
Stock and Other Ownership Interests - Aileron Therapeutics; Verastem
 
D. Allen Annis
Employment - Aileron Therapeutics
Leadership - Aileron Therapeutics
Stock and Other Ownership Interests - Aileron Therapeutics
Patents, Royalties, Other Intellectual Property - Aileron Therapeutics (Inst)
 
Manuel Aivado
Employment - Aileron Therapeutics
Leadership - Aileron Therapeutics
Stock and Other Ownership Interests - Aileron Therapeutics
Patents, Royalties, Other Intellectual Property - Aileron Therapeutics (Inst)
 
Manish R. Patel
Honoraria - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Medivation
Consulting or Advisory Role - Guardant Health
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Medivation